121 related articles for article (PubMed ID: 8817726)
21. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.
Gelding SV; Taylor NF; Wood PJ; Noonan K; Weaver JU; Wood DF; Monson JP
Clin Endocrinol (Oxf); 1998 Feb; 48(2):153-62. PubMed ID: 9579226
[TBL] [Abstract][Full Text] [Related]
22. Effect of metyrapone on the pituitary-adrenal axis in depression: relation to dexamethasone suppressor status.
Ur E; Dinan TG; O'Keane V; Clare AW; McLoughlin L; Rees LH; Turner TH; Grossman A; Besser GM
Neuroendocrinology; 1992 Oct; 56(4):533-8. PubMed ID: 1335555
[TBL] [Abstract][Full Text] [Related]
23. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging.
Wilkinson CW; Peskind ER; Raskind MA
Neuroendocrinology; 1997 Jan; 65(1):79-90. PubMed ID: 9032777
[TBL] [Abstract][Full Text] [Related]
24. Effects of total sleep deprivation on urinary cortisol, self-rated arousal, and mood in depressed patients.
Bouhuys AL; Flentge F; Van den Hoofdakker RH
Psychiatry Res; 1990 Nov; 34(2):149-62. PubMed ID: 2287648
[TBL] [Abstract][Full Text] [Related]
25. Hypothalamic-pituitary-adrenal axis interaction with prostaglandins.
Thorén M; Stenfors C; Apéria B; Mathé AA
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(3):319-26. PubMed ID: 2359842
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous afternoon plasma cortisol in depression.
Christensen P; Gram LF; Kragh-Søensen P; Christensen L; Kristensen CB; Pedersen OL; Thomsen HY
J Affect Disord; 1985; 8(3):271-8. PubMed ID: 3160738
[TBL] [Abstract][Full Text] [Related]
27. Single dose metyrapone test: 11 beta-hydroxylase inhibition by metyrapone and reduced metyrapone assayed by radioimmunoassay.
Meikle AW; West SC; Weed JA; Tyler FH
J Clin Endocrinol Metab; 1975 Feb; 40(2):290-5. PubMed ID: 1128651
[TBL] [Abstract][Full Text] [Related]
28. Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication.
Takebayashi M; Kagaya A; Uchitomi Y; Kugaya A; Muraoka M; Yokota N; Horiguchi J; Yamawaki S
J Neural Transm (Vienna); 1998; 105(4-5):537-42. PubMed ID: 9720981
[TBL] [Abstract][Full Text] [Related]
29. Evidence against changes in corticotroph CRF receptors in depressed patients.
Young EA; Akil H; Haskett RF; Watson SJ
Biol Psychiatry; 1995 Mar; 37(6):355-63. PubMed ID: 7772643
[TBL] [Abstract][Full Text] [Related]
30. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
31. The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis--which tests should be used?
Holt PR; Lowndes DW; Smithies E; Dixon GT
Clin Exp Allergy; 1990 Mar; 20(2):145-9. PubMed ID: 2357614
[TBL] [Abstract][Full Text] [Related]
32. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
[TBL] [Abstract][Full Text] [Related]
33. [Clinical effects of cortisol synthesis inhibition on treatment-resistant depression].
Iizuka H; Kishimoto A; Nakamura J; Mizukawa R
Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Feb; 16(1):33-6. PubMed ID: 8640461
[TBL] [Abstract][Full Text] [Related]
34. Dehydroepiandrosterone (DHEA) treatment of depression.
Wolkowitz OM; Reus VI; Roberts E; Manfredi F; Chan T; Raum WJ; Ormiston S; Johnson R; Canick J; Brizendine L; Weingartner H
Biol Psychiatry; 1997 Feb; 41(3):311-8. PubMed ID: 9024954
[TBL] [Abstract][Full Text] [Related]
35. Quantitation of the accelerating effect of metyrapone on cortisol metabolism.
Blichert-Toft M; Kehlet H
Clin Endocrinol (Oxf); 1976 May; 5(3):295-8. PubMed ID: 954224
[TBL] [Abstract][Full Text] [Related]
36. Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients.
Young EA; Haskett RF; Grunhaus L; Pande A; Weinberg VM; Watson SJ; Akil H
Arch Gen Psychiatry; 1994 Sep; 51(9):701-7. PubMed ID: 8080346
[TBL] [Abstract][Full Text] [Related]
37. The metyrapone test in affective disorders and schizophrenia II. Changes upon treatment.
Perini GI; Fava GA; Morphy MA; Carson SW; Molnar G; Jusko WJ
J Affect Disord; 1984 Dec; 7(3-4):265-72. PubMed ID: 6151957
[TBL] [Abstract][Full Text] [Related]
38. Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone.
Jahn H; Kiefer F; Schick M; Yassouridis A; Steiger A; Kellner M; Wiedemann K
Sleep; 2003 Nov; 26(7):823-9. PubMed ID: 14655915
[TBL] [Abstract][Full Text] [Related]
39. The assessment of the functional capacity of the hypothalamic-pituitary-adrenal axis by measurement of basal plasma and urinary cortisol in comparison with insulin-induced hypoglycaemia and metyrapone tests.
de Lange WE; Sluiter WJ
Neth J Med; 1993 Aug; 43(1-2):64-8. PubMed ID: 8232696
[TBL] [Abstract][Full Text] [Related]
40. Preoperative management of Cushing's syndrome with metyrapone for severe psychiatric disturbances.
Obinata D; Yamaguchi K; Hirano D; Yoshida T; Soma M; Takahashi S
Int J Urol; 2008 Apr; 15(4):361-2. PubMed ID: 18380829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
